CXCR4 and prostate cancer: According to a recent study, ROSI is capable of downregulating C-X-C motif chemokine 12 (CXCL12)-induced migration, invasion and PI3K/Akt activation in a prostate cancer cell line, through the inhibition of the CXCL12/C-X-C chemokine receptor type 4 (CXCR4) axis (100).